A randomised, double-blind, vehicle-controlled, multi-centre, parallel-group study to investigate the safety, tolerability, and efficacy of GR1014 cutaneous gel as a topical radioprotector in the prevention of the radiodermatitis occurring with adjuvant radiotherapy for localised breast cancer after lumpectomy
Latest Information Update: 06 Aug 2024
At a glance
- Drugs GR 1014 (Primary)
- Indications Radiodermatitis
- Focus Therapeutic Use
- Acronyms GuARD
- Sponsors Graegis Pharmaceuticals
Most Recent Events
- 06 Aug 2024 New trial record